Author

Richard Z. Xie

Observed names: Richard Xie, Richard Z Xie

Observed institution: Emory University

ORCID: 0000-0002-2797-3019

Observed ORCID: 0000-0002-2797-3019

OpenAlex ID: A5089776706

Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States

2021 · Richard Z. Xie, Erica deFur Malik, et al. · PharmacoEconomics · 38

Preferences for Treatments for Major Depressive Disorder: Formative Qualitative Research Using the Patient Experience

2022 · Susan dosReis, Laura M. Bozzi, et al. · Patient · 7

Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States

2023 · Lia N Pizzicato, Richard Z Xie, et al. · Journal of Managed Care & Specialty Pharmacy · 4

Patient-Informed Value Elements in Cost-Effectiveness Analyses of Major Depressive Disorder Treatment: A Literature Review and Synthesis

2024 · Julia F. Slejko, T. Joseph Mattingly, et al. · Value in Health · 3

A virtual innovation bootcamp to remotely connect and empower students to solve COVID-19-related medical problems

2022 · Mario V. Russo, Abhinav J. Appukutty, et al. · Nature Biotechnology · 2

Patient Perspectives: An Integral Part of Health Technology Assessment Methodology

2022 · Jason Spangler, Tiffany Huth, et al. · International Journal of Technology Assessment in Health Care · 2

Advancing Methods to Measure and Reward Healthcare Innovation

2024 · Richard Chapman, Richard Xie · PharmacoEconomics · 1

Treatment goals for rheumatoid arthritis: patient engagement and goal collection

2023 · Zachary Predmore, Emily K Chen, et al. · Journal of Comparative Effectiveness Research · 1

Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital

2026 · Richard Z Xie · Journal of Comparative Effectiveness Research

Drug woes won’t be tamed by US price regulations

2025 · Richard Xie · Nature

HPR28 Are We Getting Good Value for Innovative Therapies in the US? Findings From Generalized Cost-Effectiveness Analyses (GCEAs)

2025 · Richard Xie, Peter Rubin, et al. · Value in Health

HTA363 What Generalized Cost-Effectiveness Analysis (GCEA) Reveals About the Applicability of Foreign Reference Pricing in Medicare Price Negotiation in the US

2025 · Richard Xie, Peter Rubin, et al. · Value in Health

HPR185 Small Molecules vs. Biologics Patterns of Indication Expansion and the Potential Impact of Medicare Price Negotiation

2025 · Cheyi Li, Richard Xie, et al. · Value in Health

EE751 What Are the Biggest Value Drivers? A Comparison of the Relative Impacts of Six Novel Value Elements on Value Estimates Across Twelve Treatments Through Generalized Cost-Effectiveness Analyses

2025 · Richard Xie, Peter Rubin, et al. · Value in Health

Works count: 14

Citation count: 58

H-index: 3

I10-index: 1